Yoshiaki Ohashi - Chugai Pharmaceutical Director
| CHGCY Stock | USD 21.00 0.70 3.45% |
Director
Yoshiaki Ohashi is Executive Officer, Chief Director of Drug Safety, Manager of Regulatory & Quality Management Unit of Chugai Pharmaceutical Co since 2018.
| Age | 63 |
| Tenure | 6 years |
| Phone | 81 3 3281 6611 |
| Web | https://www.chugai-pharm.co.jp |
Chugai Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.1956 % which means that it generated a profit of $0.1956 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2867 %, meaning that it generated $0.2867 on every $100 dollars invested by stockholders. Chugai Pharmaceutical's management efficiency ratios could be used to measure how well Chugai Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Ann Fudge | Novartis AG ADR | 70 | |
| Vicki Sato | Bristol Myers Squibb | 71 | |
| Thomas Cech | Merck Company | 72 | |
| Michael Bonney | Bristol Myers Squibb | 61 | |
| Marillyn Hewson | Johnson Johnson | 67 | |
| Leslie Brun | Merck Company | 68 | |
| Philip Broadley | AstraZeneca PLC ADR | 52 | |
| Andreas Planta | Novartis AG ADR | 65 | |
| Harry Dietz | GlaxoSmithKline PLC ADR | 62 | |
| Judy Lewent | GlaxoSmithKline PLC ADR | 71 | |
| Jesse Goodman | GlaxoSmithKline PLC ADR | 69 | |
| Pamela Craig | Merck Company | 64 | |
| Anne Mulcahy | Johnson Johnson | 68 | |
| Marc Dunoyer | AstraZeneca PLC ADR | 72 | |
| Deborah DiSanzo | AstraZeneca PLC ADR | 59 | |
| Wyllie Cornwell | Pfizer Inc | 71 | |
| Susan Hockfield | Pfizer Inc | 70 | |
| Thomas Glocer | Merck Company | 61 | |
| Julia Haller | Bristol Myers Squibb | 66 | |
| Hubert Joly | Johnson Johnson | 61 | |
| Mike Ciaffi | Scilex Holding | N/A | |
Management Performance
Chugai Pharmaceutical Leadership Team
Elected by the shareholders, the Chugai Pharmaceutical's board of directors comprises two types of representatives: Chugai Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chugai. The board's role is to monitor Chugai Pharmaceutical's management team and ensure that shareholders' interests are well served. Chugai Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chugai Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Junichi Ebihara, VP and General Manager of Legal Department | ||
| Toshiya Sasai, Exec Department | ||
| Shinji Hidaka, Executive Officer, Deputy Chief Director of Sales, Manager of Primary Unit | ||
| Osamu Okuda, Executive Officer, Director of Business Planning | ||
| Yoshiaki Ohashi, Executive Officer, Chief Director of Drug Safety, Manager of Regulatory & Quality Management Unit | ||
| Tetsuya Yamaguchi, Executive Officer, Director of Business Development | ||
| Masahiko Uchida, Gen Department | ||
| Yoshiyuki Yano, Executive Officer, Director of Human Resources | ||
| Tsunanori Sato, Executive Officer, Chief Director of Sales | ||
| Toshiaki Itagaki, VP and General Manager of Fin. and Accounting Department |
Chugai Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Chugai Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.29 | |||
| Return On Asset | 0.2 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 0.42 % | |||
| Current Valuation | 39.67 B | |||
| Shares Outstanding | 3.29 B | |||
| Price To Earning | 22.15 X | |||
| Price To Book | 4.62 X | |||
| Price To Sales | 0.04 X | |||
| Revenue | 999.76 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Chugai Pink Sheet Analysis
When running Chugai Pharmaceutical's price analysis, check to measure Chugai Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chugai Pharmaceutical is operating at the current time. Most of Chugai Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Chugai Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chugai Pharmaceutical's price. Additionally, you may evaluate how the addition of Chugai Pharmaceutical to your portfolios can decrease your overall portfolio volatility.